Diversified Trust CO Fate Therapeutics Inc Transaction History

Diversified Trust CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 17, 2023	SELL	$2.02 - $5.04 $22,941 - $57,239	-11,357 Reduced 48.03%	12,287 $26,000
Q2 2023 Jul 18, 2023	BUY	$4.76 - $6.59 $54,059 - $74,842	11,357 Added 92.43%	23,644 $112,000
Q4 2022 Jan 17, 2023	BUY	$9.86 - $23.83 $6,063 - $14,655	615 Added 5.27%	12,287 $124,000
Q3 2022 Oct 14, 2022	SELL	$21.04 - $36.06 $8,121 - $13,919	-386 Reduced 3.2%	11,672 $262,000
Q4 2021 Jan 13, 2022	BUY	$47.84 - $64.34 $36,071 - $48,512	754 Added 6.67%	12,058 $706,000
Q2 2021 Jul 20, 2021	BUY	$67.25 - $92.52 $399,666 - $549,846	5,943 Added 110.86%	11,304 $981,000
Q1 2021 May 10, 2021	BUY	$72.16 - $117.4 $386,849 - $629,381	5,361 New	5,361 $442,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Diversified Trust CO, based on Form 13F filings with the SEC.

Stay updated on Diversified Trust CO with notifications on news.